'I am energized to join the Endo team, and for the opportunity to help advance Endo's on-going transformation and to deliver its strategic priority to expand and enhance its portfolio and help everyone they serve live their best life,' said James Tursi, MD.
'His broad therapeutic expertise, including in the areas of urology, orthopedics, and pediatric endocrinology, along with his in-depth experience with XIAFLEX ® and collagenase clostridium histolyticum will be invaluable as we pursue our mission to develop and deliver life enhancing products.' Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience,' said Blaise Coleman, Endo's President and Chief Executive Officer. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. 11, 2022 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr.
